Skip to main content
. 2019 Dec 7;20(24):6175. doi: 10.3390/ijms20246175

Figure 1.

Figure 1

SYK inhibition in ETV6-RUNX1 cell lines enhances the efficacy of conventional chemotherapeutics. (a) Western blot analysis for SYK Y525 and its total form in ETV6-RUNX1-positive (AT-1, AT-2 and REH) and negative (NALM-6 and RCH-ACV) cell lines. (b) Cell viability measured by MTT test of ETV6-RUNX1 cell lines treated for 72 h with SYK inhibitors. All experiments were performed at least three times, and data are represented as mean ± SEM. (c) Reduction of cell viability, determined by MTT test, in AT-1, AT-2 and REH cells after 48 h of treatment with entospletinib and 1 unit of VDA (corresponding to a cocktail of 1 nM VCR, dex and AraC respectively) alone or in combination (n = at least three for all experiments). Results are presented as means ± SEM. (d) Increased cell death determined by Annexin V/PI staining after 48 h of treatment. AT-1, AT-2 and REH cells were treated with 1 unit of VDA and 50 μM of entospletinib (ento) alone or in combination. The percentage of dead cells, defined as the total of Annexin V+/PI−, Annexin V+/PI+ and Annexin V−/PI+, was established after normalizing on DMSO-treated cells. Paired t test; * p ≤ 0.05, ** p ≤ 0.01; *** p ≤ 0.001; n = 3 for all experiments. Results are presented as means ± SEM. VDA and ento concentrations used in these experiments were selected on the basis of MTT test results, by choosing the ones most able to reduce cell viability in combination.